Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Eli Lilly shares rose more than 1% premarket Thursday ... and revenue despite another sales miss for its obesity and diabetes drugs. The company reported Q4 earnings per share (EPS) of $5.32, beating ...

Reports Q4 revenue $13.53B, consensus $13.43B. “2024 was a highly successful year for Lilly,” said David Ricks, Lilly’s chair and CEO. “We had ...

Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Lilly expects full-year earnings in the range of $22.50 to $24 per share, with revenue in the range of $58 billion to $61 billion. This story was generated by Automated Insights ( ...

Eli Lilly (NYSE:LLY) is scheduled to announce Q4 earnings results on Thursday, February 6th, before market open. The ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.